Artacent

Artacent is a dual-layer amniotic membrane (DLAM) biologic developed by Tides Medical and clinically evaluated by SerenaGroup for the treatment of chronic diabetic foot ulcers. The product is composed of two layers of dehydrated human amniotic membrane, harvested from placentas during planned Caesarean sections, which are cleaned, decellularized, and folded with the stromal sides facing outward. Artacent serves as a biological scaffold that contains essential growth factors intended to induce angiogenesis, stimulate the proliferation of human dermal fibroblasts, and recruit stem cells necessary for wound repair and tissue regeneration. It is FDA-cleared for homologous use under the 361 HCT/P regulatory pathway and is applied topically to debrided, clean, and uninfected wounds.

Brand names

Artacent

Other names

Dual Layer Amniotic MembraneDLAM